Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $21.75

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.75.

Several equities analysts have recently issued reports on VTYX shares. Wells Fargo & Company raised Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Lifesci Capital raised Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Canaccord Genuity Group reduced their price objective on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Finally, Oppenheimer raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research note on Tuesday, March 12th.

Hedge Funds Weigh In On Ventyx Biosciences

A number of large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ventyx Biosciences by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,506 shares of the company’s stock valued at $52,000 after purchasing an additional 739 shares during the last quarter. JSF Financial LLC acquired a new position in Ventyx Biosciences during the third quarter worth $208,000. Rafferty Asset Management LLC bought a new position in Ventyx Biosciences in the third quarter valued at $209,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Ventyx Biosciences by 36.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,855 shares of the company’s stock valued at $273,000 after buying an additional 2,078 shares during the last quarter. Finally, Norden Group LLC bought a new stake in Ventyx Biosciences during the 1st quarter worth about $59,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 3.6 %

NASDAQ VTYX opened at $4.44 on Monday. The firm has a market cap of $313.02 million, a price-to-earnings ratio of -1.35 and a beta of 0.48. Ventyx Biosciences has a 1-year low of $1.87 and a 1-year high of $40.58. The company has a 50 day moving average of $5.96 and a 200-day moving average of $4.72.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same quarter last year, the firm posted ($0.62) earnings per share. On average, analysts forecast that Ventyx Biosciences will post -2.55 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.